Form 8-K Cadrenal Therapeutics, For: Jul 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Cadrenal Therapeutics CMO resigns, separation terms disclosed
July 17, 2026 4:21 PM EDTCadrenal Therapeutics (NASDAQ: CVKD) has entered into a separation agreement with James J. Ferguson III, its Chief Medical Officer, following his resignation announced July 7, 2026.
According to a company statement, Dr. Ferguson notified the board of his decision to resign effective July 31, 2026. The separation... More
